Previous 10 | Next 10 |
MENLO PARK, Calif., July 08, 2019 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced presentations at the following upcoming conferences: Event: American Socie...
This is a special contribution article by Prof. Grant Henning based on his published research on the BLM technical theory . The model, his trailing stop-loss approach, and comments are expressly based on his own proprietary methodology and forecasts in the references below. Winning Bounc...
Note: This article was first made available to members of my exclusive community, The Formula , on May 14 when shares of Adverum ( ADVM ) were trading just over $6. Read: Adverum's most quarterly filing Read: ADVM-022 article (preclinical findings) Gene therapy - op...
This is a special contribution article by Prof. Grant Henning based on his published research on the BLM technical theory . The model, his trailing stop-loss approach, and comments are expressly based on his own proprietary methodology and forecasts in the references below. The Bounce/Lag...
-- Continued Progress in the OPTIC Phase 1 Clinical Trial -- Patients Receiving Single Intravitreal Injection of ADVM-022 Dosed at 2 x 10^11 vg/eye MENLO PARK, Calif., June 10, 2019 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy comp...
This is a special contribution article by Prof. Grant Henning based on his published research on the BLM technical theory . The model, his trailing stop-loss approach, and comments are expressly based on his own proprietary methodology and forecasts in the references below. Winning Bounc...
Today, we talk about Adverum Biotechnologies ( ADVM ), a stock that has gained 12.79% in the past one week, 38.52% in the past one month, and 191.11% in 2019 YTD. The stock has come 250.00% above its 52-week low of $2.62 and is now just 2.96% lower than its 52-week high of $9.45. Trading at ar...
Words rich in meaning can be cheap in sound effects ." - Dejan Stojanovic Today, we revisit a 'Busted IPO' that has been 'en fuego' so far in 2019. The stock added some 40% to its recent gains this week even as the overall market sank. We will discuss recent events and revisit this small ...
The iShares Russell 2000 ETF ( IWM ) tracks a basket of small-cap stocks including companies not typically part of large-cap broad market indexes like the S&P 500. Year to date, the ETF is up 15%, but still 10% below its all-time high set in August of 2018, which is in contrast to the S&am...
Gainers: Eltek (NASDAQ: ELTK ) +70% . Iovance Biotherapeutics (NASDAQ: IOVA ) +33% . Adverum Biotechnologies (NASDAQ: ADVM ) +25% . Charah Solutions (NYSE: CHRA ) +19% . KEMET Corporation (NYSE: KEM ) +17% . Mirati Therapeutics (NASDAQ: MRTX ) +16% . Danaos Corporation (NYSE: D...
News, Short Squeeze, Breakout and More Instantly...
Adverum Biotechnologies Inc. Company Name:
ADVM Stock Symbol:
NASDAQ Market:
- Phase 2 LUNA interim analysis to be presented at ASRS Annual Scientific Meeting on July 17th, 2024 in Stockholm, Sweden - $193.3 million in cash...
- Phase 2 LUNA interim analysis to be presented at ASRS Annual Scientific Meeting on July 17 th , 2024 in Stockholm, Sweden - $193.3 million in cash, cash equivalents and short-term investments expected to fund operations into late 2025 REDWOOD CITY, Calif., May 09, 20...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...